RET and medullary thyroid gland carcinoma: Moreover, 94.8% of the 194 patients with MEN2A presented with MTC (i.e., 100% of 98 patients with an ATA-H mutation [C634] and 89.6% of 96 patients with an ATA-MOD mutation had MTC).